Bega Group to close peanut processing business
The decision will result in a phased shutdown of PCA's facilities in Kingaroy and Tolga in Queensland, over the next 18 months.
The site in Kingaroy was acquired in 2017 when what was then Bega Cheese bought PCA.
In 2022, Bega Cheese renamed itself the Bega Group to better represent its portfolio, including Bega cheese, peanut butter and Vegemite spreads.
In a statement issued today (9 July), Bega Group said PCA faced 'sustained' financial strain for years before its acquisition, with annual losses of A$5–10m ($3.27–6.54m).
Despite 'ongoing investments', Bega Group said it could not 'establish a sustainable business model' for the operation.
'Continued financial losses and industry challenges led to the need for the review and ultimately the conclusion that the business would be better served by a change to more local and focused ownership or in the absence of that being achieved, unfortunately a closure,' the statement read.
Bega Group started a strategic review of its peanut processing assets in June 2024.
CEO Pete Findlay said: 'We announced the strategic review over 12 months ago and we have pursued several options to sell the business. Unfortunately, we've been unable to secure a buyer that could sustain a long-term future for employees and growers.'
The decision puts approximately 150 jobs at risk.
Findlay added: 'We understand the impact this decision will have, and we will work closely with growers and the approximately 150 employees at the Kingaroy and Tolga facilities to support them through this period.'
A spokesperson of the company told Just Food the closure affects only PCA's 'raw' peanut processing business, with peanut butter production continuing at Port Melbourne.
PCA, with annual sales of about A$19m, operates additional facilities in Gayndah and Inverlaw.
The Gayndah site, an 'overflow site', was sold separately before this announcement. The future of the Inverlaw site is still being considered, according to the statement.
The spokesperson added: 'We are taking this transition very seriously and we will be consulting with local community groups throughout this process.'
In May, the company announced the closure of its cheese processing and packaging facility in Strathmerton in Victoria.
In February 2023, the group announced the closure of its milk manufacturing plant in Canberra, with production relocated to a site in Penrith, New South Wales.
For the first half of its 2025 financial year, Bega Group reported a 3% increase in revenue to A$1.78bn for the period ended 29 December 2024.
EBITDA rose by 27% to A$109.3m. Earnings per share (EPS) grew by 14% year-on-year to 9.9 cents.
"Bega Group to close peanut processing business" was originally created and published by Just Food, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
23-07-2025
- Business Wire
AngioDynamics Announces Publication of PRESERVE Study of NanoKnife ® System for Prostate Tissue Ablation in European Urology
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the publication of results from the PRESERVE study, which assessed the safety and effectiveness of irreversible electroporation (IRE) with the NanoKnife System to ablate prostate tissue in patients with intermediate-risk prostate cancer (PCa), in European Urology, a leading journal in urologic research that delivers high-impact research informing clinical practice and policy worldwide, including in the United States, titled 'Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial.' Prostate cancer is the second most common cancer among men in the United States. 1 For many, especially those diagnosed at an early stage with less aggressive tumors, active surveillance remains the preferred initial management strategy. 2 The NanoKnife System is a leading non-thermal, radiation-free, ablation technology designed to treat prostate tissue by using IRE technology, offering patients a minimally invasive option for prostate treatment. 'The publication of the PRESERVE study in European Urology provides strong supporting evidence for the use of Irreversible Electroporation as a focal therapy in prostate treatment,' said Juan Carlos Serna, AngioDynamics Senior Vice President of Scientific and Clinical Affairs. 'This is an important milestone for patients and providers seeking new options beyond traditional whole-gland therapies. These results reinforce the NanoKnife System's role in helping patients receive effective treatment while preserving quality of life, particularly urinary and sexual function, which are often impacted by conventional treatments.' The NanoKnife System received FDA clearance for prostate tissue ablation in late 2024, following the successful completion of the PRESERVE study. Conducted across 17 clinical sites in collaboration with the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), the trial enrolled 121 patients who met the key inclusion criteria: age >50 yr with organ-confined, grade group 2 or 3 PCa, clinical stage ≤T2c, prostate-specific antigen (PSA) ≤15 ng/mL, or PSA density <0.15 ng/mL 2. The PRESERVE clinical study met its primary effectiveness endpoint, demonstrating the performance of the NanoKnife System for the ablation of prostate tissue in patients with intermediate-risk PCa. At 12 months post-procedure, 84.0% of men were free from in-field, clinically significant disease (defined by the Delphi consensus criterion). The study also demonstrated strong quality-of-life outcomes: urinary continence was largely preserved (97% at baseline vs. 96% at 12 months), and at 12 months, 84% of patients with good baseline sexual function maintained erections sufficient for penetration. 3 These results confirm the NanoKnife System's robust safety and efficacy profile, building on a foundation of more than 32 clinical studies involving over 2,600 patients worldwide. 3 The PRESERVE study was led by Co-Principal Investigators Jonathan Coleman, MD, a urologic surgeon at Memorial Sloan Kettering Cancer Center, and Arvin George, MD, a urologic oncologist at Johns Hopkins Medicine. Dr. George previously practiced at the Veterans Affairs Ann Arbor Healthcare System and Michigan Medicine. 'The PRESERVE data supports the long-term data that we are seeing in practice, patients are benefiting from effective, targeted treatment without compromising their quality of life,' said Dr. Coleman. 'The ability to preserve urinary and sexual function while treating prostate tissue with precision is a meaningful advancement for both clinicians and patients.' The NanoKnife System uses a non-thermal technique called irreversible electroporation (IRE) to ablate targeted prostate tissue while sparing critical structures. Unlike thermal ablation, IRE avoids damaging critical structures, helping preserve urinary and sexual function. The PRESERVE results arrive at a pivotal time, as global urologic societies increasingly recognize focal therapy, and patients seek alternatives to whole-gland treatments that may carry a greater risk of side effects. For more information on the NanoKnife System and focal therapy in prostate tissue, visit: For important risk information, visit About European Urology European Urology is ranked the top urology journal in the world by the Scimago Journal Rank (SJR). The journal is recognized globally for its high-impact research across oncology, surgical innovation, and more. This ranking reaffirms its role as the premier publication advancing urologic science and care. 4 About the NanoKnife System The NanoKnife System utilizes Irreversible Electroporation (IRE) technology to effectively destroy targeted cells without the use of thermal energy by delivering high-voltage pulses, creating permanent nanopores within the cell membrane. This stimulus induces an apoptotic-like cellular death in the targeted tissue, resulting in a complete ablation of the targeted tissue. 5 Visit for full product information. United States: The NanoKnife System with six outputs is indicated for surgical ablation of soft tissue, including prostate tissue. Canada: The NanoKnife System is a medical device for cell membrane electroporation. Electroporation is a phenomenon that occurs in cell membranes as cells are exposed to an electrical field of sufficiently high intensity. The electric field acts as a physical stimulus, bringing about alterations in cell membranes that result in increased permeability. European Union: The NanoKnife System is indicated for the ablation of prostate tissue in patients with intermediate risk prostate cancer. About AngioDynamics, Inc. AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life. The Company's innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit Safe Harbor This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as 'expects,' 'reaffirms,' 'intends,' 'anticipates,' 'plans,' 'believes,' 'seeks,' 'estimates,' 'projects,' 'optimistic,' or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign healthcare reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, tariffs, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2025. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason. AngioDynamics, the AngioDynamics logo, and NanoKnife are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or subsidiary. All other trademarks are the property of their respective owners. © 2025 AngioDynamics, Inc.
Yahoo
09-07-2025
- Yahoo
Bega Group to close peanut processing business
Australia's Bega Group is to close its peanut processing arm, the Peanut Company of Australia (PCA). The decision will result in a phased shutdown of PCA's facilities in Kingaroy and Tolga in Queensland, over the next 18 months. The site in Kingaroy was acquired in 2017 when what was then Bega Cheese bought PCA. In 2022, Bega Cheese renamed itself the Bega Group to better represent its portfolio, including Bega cheese, peanut butter and Vegemite spreads. In a statement issued today (9 July), Bega Group said PCA faced 'sustained' financial strain for years before its acquisition, with annual losses of A$5–10m ($3.27–6.54m). Despite 'ongoing investments', Bega Group said it could not 'establish a sustainable business model' for the operation. 'Continued financial losses and industry challenges led to the need for the review and ultimately the conclusion that the business would be better served by a change to more local and focused ownership or in the absence of that being achieved, unfortunately a closure,' the statement read. Bega Group started a strategic review of its peanut processing assets in June 2024. CEO Pete Findlay said: 'We announced the strategic review over 12 months ago and we have pursued several options to sell the business. Unfortunately, we've been unable to secure a buyer that could sustain a long-term future for employees and growers.' The decision puts approximately 150 jobs at risk. Findlay added: 'We understand the impact this decision will have, and we will work closely with growers and the approximately 150 employees at the Kingaroy and Tolga facilities to support them through this period.' A spokesperson of the company told Just Food the closure affects only PCA's 'raw' peanut processing business, with peanut butter production continuing at Port Melbourne. PCA, with annual sales of about A$19m, operates additional facilities in Gayndah and Inverlaw. The Gayndah site, an 'overflow site', was sold separately before this announcement. The future of the Inverlaw site is still being considered, according to the statement. The spokesperson added: 'We are taking this transition very seriously and we will be consulting with local community groups throughout this process.' In May, the company announced the closure of its cheese processing and packaging facility in Strathmerton in Victoria. In February 2023, the group announced the closure of its milk manufacturing plant in Canberra, with production relocated to a site in Penrith, New South Wales. For the first half of its 2025 financial year, Bega Group reported a 3% increase in revenue to A$1.78bn for the period ended 29 December 2024. EBITDA rose by 27% to A$109.3m. Earnings per share (EPS) grew by 14% year-on-year to 9.9 cents. "Bega Group to close peanut processing business" was originally created and published by Just Food, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Associated Press
07-07-2025
- Associated Press
Porsche 911 Club Coupe celebrates seven decades of Porsche Club of America
A total of 70 units will be produced for sale and will be distributed between the United States and Canada. The new Club Coupe is based on the much-loved 911 Carrera T. Thus, it comes exclusively with a flat-six engine making 388 hp mated to a six-speed manual transmission including a walnut shift lever, and an extensive list of performance-enhancing equipment, including the PASM Sport Suspension with a 10 mm lower ride height compared to a standard 911 Carrera, and a mechanical limited slip differential with Porsche Torque Vectoring (PTV). The Porsche Parade is an annual weeklong event organized by the PCA and held at different locations each year in celebration of the marque. It serves as a destination for PCA members and brand enthusiasts to congregate around their shared passion for Porsche. The event includes autocross and concourse competitions, rallies, exhibits and informational events. 'Passion drives Porsche – pure and simple. PCA members are some of the most passionate, not just in our little world but across the auto industry in general,' said Timo Resch, President and CEO of Porsche Cars North America. 'The sense of community and excitement they create is unmistakable, so it is an honor and a privilege to create a special model celebrating 70 years of the PCA.' Beyond its inherent performance credentials, the new Club Coupe is a visual standout thanks to its Paint to Sample Sholar Blue paint finish – a new metallic take on the Club Blau paint which was first used in 2015 on the second iteration of the PCA Club Coupe. The new color is a result of many iterations and collaborative discussions between the Style Porsche, Exclusive Manufaktur, and the PCA since the beginning of 2023. A standard SportDesign front fascia with red accents, and 20/21-inch RS Spyder wheels finished in Satin Black with Brilliant Silver accents give the car an even sportier appearance. Meanwhile, the Club Coupe logo on the doors in Brilliant Silver, the rear 911 decal in Brilliant Silver, and grille slat inlays in Guards Red pay homage to the PCA signature colors. The standard Vanadium Grey mirrors of the Carrera T model are instead painted in Sholar Blue to bring in even more of the special color. Finally, a special '70 year PCA' grille badge offers a subtle nod to the tradition these cars carry forward. The interior is just as special. Upon opening the doors, you are greeted with illuminated door sills with the 'PORSCHE CLUB OF AMERICA' illuminated lettering in the specific font as well as a door projector with the PCA 70 year logo. A black leather interior with deviated stitching in Speed Blue and Guards Red continue the motif along with seat belts and the steering wheel 12 o'clock marker in Guards Red. Other custom interior flourishes courtesy of Porsche Exclusive Manufaktur include the PCA 70 year logo embossed on the center console lid and a 'Club Coupe' logo on the dashboard trim. An extended equipment package is available as an option and adds popularly specified content to the car. The package includes tartan fabric seat centers in a specific PCA 70 year pattern, plus stitching in Speed Blue and the leather seat release pull loop in Guards Red. The leather owner's manual wallet also gets Speed Blue stitching and bears 'Club Coupe 70 Years Porsche Club of America' embossment. The key is painted in Sholar Blue and comes in a black leather key pouch with Speed Blue stitching and an embossed Club Coupe logo. Exclusively for owners of the Porsche 911 Club Coupe, Porsche Design created the Chronograph 1 - 911 Club Coupe. Handcrafted in Solothurn, Switzerland, this limited-edition timepiece features unique design elements that are inspired by the 911 Club Coupe and brings 70 years of Porsche Club of America heritage to the wrist. The COSC-certified chronograph is equipped with the Porsche Design caliber WERK 01.140. The clear sapphire crystal case back shows the rotor in the wheel design of the 911 Club Coupe in Satin Black and Brilliant Silver with the monochrome Porsche Crest as a center cap. The matte black dial with white hour indices with Super-LumiNova® luminous material features a 'Club Coupe' model designation and 'PORSCHE CLUB OF AMERICA' lettering. Owners will have the option to wear the timepiece with a titanium bracelet or textile Velcro strap in Porsche Club of America colors with PCA branding. 'Porsche Exclusive Manufaktur make dreams come true every day,' said Aaron Ambrosino, President of the Porsche Club of America. 'This car is a symbol of what the PCA, the world's largest club for Porsche owners, stands for. We are excited that every unit will go to PCA members and look forward to seeing them at events for many years to come.' The newest Club Coupe brings with it an impressive standard equipment list that includes a Sport Exhaust system, mechanical limited slip differential, Porsche Active Suspension Management (PASM) Sport chassis, rear axle steering, the Sport Chrono package, and a GT Sport steering wheel. The brakes of the current 911 Carrera T are also upgraded compared to the predecessor model with six-piston fixed calipers on the front axle and four-piston calipers on the rear axle, both squeezing 350 millimeter vented and cross-drilled brake rotors. Perhaps most importantly, the car is a deliberate nod to the enthusiasm for driving that the PCA embodies. Because it is based on the current 911 Carrera T, it focuses on the essentials of driving joy: minimal weight, a manual transmission and an especially capable chassis that begs to be driven. The first example of the new 911 Club Coupe, which is not part of the total 70 unit run, will be added to the Porsche Museum collection. The second example will be raffled off to the PCA, and all subsequent models will be initially offered for sale to PCA members. Production will begin this fall and run through spring, 2026. Pricing will be announced in due course. History of PCA special editions: The PCA Club Coupe tradition began in 2005 when Porsche created a 50-unit limited run of the 911 Carrera S Club Coupe (997.1 generation) to celebrate its semi-centenary anniversary. The debut occurred at the Porsche Parade in 2005 in Hershey, Pa. The first car was part of the 2005 model year and went into the Porsche Museum collection. The next unit was the first-ever car to be offered as a raffle prize to PCNA members, and all subsequent examples were offered for sale within the club. The original 911 Club Coupe had stainless steel doorsills with the 911 Club Coupe logo, a badge on the driver's side door trim indicating its individual number in the series of 50 cars, and an X51 Powerkit that increased added 26 hp and 11 lb.-ft. of torque to the 3.8-liter, flat-six cylinder of the Carrera S. Azurro California metallic – a modern interpretation of Azure Blue, a color made popular on Porsche 356 sports cars when the PCA was founded 50 years prior – put the finishing touch on this very special model. A decade later, Porsche commemorated the 60th anniversary milestone with yet another special model: the 911 Carrera GTS Club Coupe. The debut happened at the newly opened Porsche Experience Center Atlanta in January, 2015 with a subsequent showing at Porsche Parade in French Lick, Ind. in the summer of that year. This 60-unit, limited-production model was based on the contemporary 911 Carrera GTS (991.1 generation), and benefitted from both the chassis and powertrain enhancements of the time including the wider body of the 911 Carrera 4. Its naturally aspirated 3.8-liter flat six generated 430 hp and could accelerate from a standstill to 60 mph in 3.8 seconds when paired with the seven-speed PDK transmission. Perhaps most notably, the car came finished in Club Blau, a newly created color special to the GTS Club Coupe. A ducktail rear spoiler also contributed to the striking appearance of the car, along with 20-inch wheels painted in semi-gloss black with polished wheel centers. Attachments Frank Wiesmann Porsche Cars North America, Inc. 404.539.5031 [email protected] Luke Vandezande Porsche Cars North America, Inc. 470.363.5001 [email protected]
